Conversion Surgery for Advanced Thoracic SMARCA4-Deficient Undifferentiated Tumor With Atezolizumab in Combination With Bevacizumab, Paclitaxel, and Carboplatin Treatment: A Case Report

A SMARCA4-deficient undifferentiated tumor (SMARCA4-UT) is a rapidly progressing subtype of lung cancer with a poor prognosis and causes early postoperative recurrence among operable patients. In this study, we present a case of SMARCA4-UT with vertebral and chest wall invasion that successfully und...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kei Kunimasa, MD, PhD, Jiro Okami, MD, PhD, Satoshi Takenaka, MD, PhD, Keiichiro Honma, MD, PhD, Yoji Kukita, PhD, Shigenori Nagata, MD, PhD, Takahisa Kawamura, MD, PhD, Takako Inoue, MD, Motohiro Tamiya, MD, Hanako Kuhara, MD, PhD, Kazumi Nishino, MD, PhD, Hideaki Tahara, MD, PhD, Toru Kumagai, MD, PhD
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	SMARCA4-deficient undifferentiated tumor Conversion surgery Neoadjuvant therapy Immunotherapy Case report Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/6fce6fc2448440c289bbd4912081d54c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6fce6fc2448440c289bbd4912081d54c
record_format	dspace
spelling	oai:doaj.org-article:6fce6fc2448440c289bbd4912081d54c2021-12-02T05:03:45ZConversion Surgery for Advanced Thoracic SMARCA4-Deficient Undifferentiated Tumor With Atezolizumab in Combination With Bevacizumab, Paclitaxel, and Carboplatin Treatment: A Case Report2666-364310.1016/j.jtocrr.2021.100235https://doaj.org/article/6fce6fc2448440c289bbd4912081d54c2021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2666364321000941https://doaj.org/toc/2666-3643A SMARCA4-deficient undifferentiated tumor (SMARCA4-UT) is a rapidly progressing subtype of lung cancer with a poor prognosis and causes early postoperative recurrence among operable patients. In this study, we present a case of SMARCA4-UT with vertebral and chest wall invasion that successfully underwent conversion surgery after treatment with atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin. The surgical specimen comprised SMARCA4-deficient and SMARCA2-positive adenocarcinoma, confirming intratumor heterogeneity. Gene panel analysis revealed no substantial differences in mutant gene profiles among tumors and no differences in SMARCA2 mutations. Furthermore, no recurrence occurred for 9 months after surgery. Thus, this case illustrates the possibility of multidisciplinary treatment including neoadjuvant therapy with immunotherapy and conversion surgery for SMARCA4-UT.Kei Kunimasa, MD, PhDJiro Okami, MD, PhDSatoshi Takenaka, MD, PhDKeiichiro Honma, MD, PhDYoji Kukita, PhDShigenori Nagata, MD, PhDTakahisa Kawamura, MD, PhDTakako Inoue, MDMotohiro Tamiya, MDHanako Kuhara, MD, PhDKazumi Nishino, MD, PhDHideaki Tahara, MD, PhDToru Kumagai, MD, PhDElsevierarticleSMARCA4-deficient undifferentiated tumorConversion surgeryNeoadjuvant therapyImmunotherapyCase reportNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENJTO Clinical and Research Reports, Vol 2, Iss 11, Pp 100235- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	SMARCA4-deficient undifferentiated tumor Conversion surgery Neoadjuvant therapy Immunotherapy Case report Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	SMARCA4-deficient undifferentiated tumor Conversion surgery Neoadjuvant therapy Immunotherapy Case report Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Kei Kunimasa, MD, PhD Jiro Okami, MD, PhD Satoshi Takenaka, MD, PhD Keiichiro Honma, MD, PhD Yoji Kukita, PhD Shigenori Nagata, MD, PhD Takahisa Kawamura, MD, PhD Takako Inoue, MD Motohiro Tamiya, MD Hanako Kuhara, MD, PhD Kazumi Nishino, MD, PhD Hideaki Tahara, MD, PhD Toru Kumagai, MD, PhD Conversion Surgery for Advanced Thoracic SMARCA4-Deficient Undifferentiated Tumor With Atezolizumab in Combination With Bevacizumab, Paclitaxel, and Carboplatin Treatment: A Case Report
description	A SMARCA4-deficient undifferentiated tumor (SMARCA4-UT) is a rapidly progressing subtype of lung cancer with a poor prognosis and causes early postoperative recurrence among operable patients. In this study, we present a case of SMARCA4-UT with vertebral and chest wall invasion that successfully underwent conversion surgery after treatment with atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin. The surgical specimen comprised SMARCA4-deficient and SMARCA2-positive adenocarcinoma, confirming intratumor heterogeneity. Gene panel analysis revealed no substantial differences in mutant gene profiles among tumors and no differences in SMARCA2 mutations. Furthermore, no recurrence occurred for 9 months after surgery. Thus, this case illustrates the possibility of multidisciplinary treatment including neoadjuvant therapy with immunotherapy and conversion surgery for SMARCA4-UT.
format	article
author	Kei Kunimasa, MD, PhD Jiro Okami, MD, PhD Satoshi Takenaka, MD, PhD Keiichiro Honma, MD, PhD Yoji Kukita, PhD Shigenori Nagata, MD, PhD Takahisa Kawamura, MD, PhD Takako Inoue, MD Motohiro Tamiya, MD Hanako Kuhara, MD, PhD Kazumi Nishino, MD, PhD Hideaki Tahara, MD, PhD Toru Kumagai, MD, PhD
author_facet	Kei Kunimasa, MD, PhD Jiro Okami, MD, PhD Satoshi Takenaka, MD, PhD Keiichiro Honma, MD, PhD Yoji Kukita, PhD Shigenori Nagata, MD, PhD Takahisa Kawamura, MD, PhD Takako Inoue, MD Motohiro Tamiya, MD Hanako Kuhara, MD, PhD Kazumi Nishino, MD, PhD Hideaki Tahara, MD, PhD Toru Kumagai, MD, PhD
author_sort	Kei Kunimasa, MD, PhD
title	Conversion Surgery for Advanced Thoracic SMARCA4-Deficient Undifferentiated Tumor With Atezolizumab in Combination With Bevacizumab, Paclitaxel, and Carboplatin Treatment: A Case Report
title_short	Conversion Surgery for Advanced Thoracic SMARCA4-Deficient Undifferentiated Tumor With Atezolizumab in Combination With Bevacizumab, Paclitaxel, and Carboplatin Treatment: A Case Report
title_full	Conversion Surgery for Advanced Thoracic SMARCA4-Deficient Undifferentiated Tumor With Atezolizumab in Combination With Bevacizumab, Paclitaxel, and Carboplatin Treatment: A Case Report
title_fullStr	Conversion Surgery for Advanced Thoracic SMARCA4-Deficient Undifferentiated Tumor With Atezolizumab in Combination With Bevacizumab, Paclitaxel, and Carboplatin Treatment: A Case Report
title_full_unstemmed	Conversion Surgery for Advanced Thoracic SMARCA4-Deficient Undifferentiated Tumor With Atezolizumab in Combination With Bevacizumab, Paclitaxel, and Carboplatin Treatment: A Case Report
title_sort	conversion surgery for advanced thoracic smarca4-deficient undifferentiated tumor with atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin treatment: a case report
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/6fce6fc2448440c289bbd4912081d54c
work_keys_str_mv	AT keikunimasamdphd conversionsurgeryforadvancedthoracicsmarca4deficientundifferentiatedtumorwithatezolizumabincombinationwithbevacizumabpaclitaxelandcarboplatintreatmentacasereport AT jirookamimdphd conversionsurgeryforadvancedthoracicsmarca4deficientundifferentiatedtumorwithatezolizumabincombinationwithbevacizumabpaclitaxelandcarboplatintreatmentacasereport AT satoshitakenakamdphd conversionsurgeryforadvancedthoracicsmarca4deficientundifferentiatedtumorwithatezolizumabincombinationwithbevacizumabpaclitaxelandcarboplatintreatmentacasereport AT keiichirohonmamdphd conversionsurgeryforadvancedthoracicsmarca4deficientundifferentiatedtumorwithatezolizumabincombinationwithbevacizumabpaclitaxelandcarboplatintreatmentacasereport AT yojikukitaphd conversionsurgeryforadvancedthoracicsmarca4deficientundifferentiatedtumorwithatezolizumabincombinationwithbevacizumabpaclitaxelandcarboplatintreatmentacasereport AT shigenorinagatamdphd conversionsurgeryforadvancedthoracicsmarca4deficientundifferentiatedtumorwithatezolizumabincombinationwithbevacizumabpaclitaxelandcarboplatintreatmentacasereport AT takahisakawamuramdphd conversionsurgeryforadvancedthoracicsmarca4deficientundifferentiatedtumorwithatezolizumabincombinationwithbevacizumabpaclitaxelandcarboplatintreatmentacasereport AT takakoinouemd conversionsurgeryforadvancedthoracicsmarca4deficientundifferentiatedtumorwithatezolizumabincombinationwithbevacizumabpaclitaxelandcarboplatintreatmentacasereport AT motohirotamiyamd conversionsurgeryforadvancedthoracicsmarca4deficientundifferentiatedtumorwithatezolizumabincombinationwithbevacizumabpaclitaxelandcarboplatintreatmentacasereport AT hanakokuharamdphd conversionsurgeryforadvancedthoracicsmarca4deficientundifferentiatedtumorwithatezolizumabincombinationwithbevacizumabpaclitaxelandcarboplatintreatmentacasereport AT kazuminishinomdphd conversionsurgeryforadvancedthoracicsmarca4deficientundifferentiatedtumorwithatezolizumabincombinationwithbevacizumabpaclitaxelandcarboplatintreatmentacasereport AT hideakitaharamdphd conversionsurgeryforadvancedthoracicsmarca4deficientundifferentiatedtumorwithatezolizumabincombinationwithbevacizumabpaclitaxelandcarboplatintreatmentacasereport AT torukumagaimdphd conversionsurgeryforadvancedthoracicsmarca4deficientundifferentiatedtumorwithatezolizumabincombinationwithbevacizumabpaclitaxelandcarboplatintreatmentacasereport
_version_	1718400656986865664

Conversion Surgery for Advanced Thoracic SMARCA4-Deficient Undifferentiated Tumor With Atezolizumab in Combination With Bevacizumab, Paclitaxel, and Carboplatin Treatment: A Case Report

Ejemplares similares